THE QUINOLONES. Third Edition. Edited by VINCENT T. ANDRIOLE. Yale University School of Medicine ACADEMIC PRESS

Similar documents
Cipro for gram positive cocci in urine

Objectives. Basic Microbiology. Patient related. Environment related. Organism related 10/12/2017

What s next in the antibiotic pipeline?

Medicinal Chemistry 561P. 2 st hour Examination. May 6, 2013 NAME: KEY. Good Luck!

Other Beta - lactam Antibiotics

Aminoglycosides. Spectrum includes many aerobic Gram-negative and some Gram-positive bacteria.

General Approach to Infectious Diseases

Drug Class Prior Authorization Criteria Intravenous Antibiotics

SECTION 3A. Section 3A Criteria for Optional Special Authorization of Select Drug Products

Author - Dr. Josie Traub-Dargatz

CME/CE QUIZ CME/CE QUESTIONS. a) 20% b) 22% c) 34% d) 35% b) Susceptible and resistant strains of typical respiratory

Treatment of Respiratory Tract Infections Prof. Mohammad Alhumayyd Dr. Aliah Alshanwani

9/30/2016. Dr. Janell Mayer, Pharm.D., CGP, BCPS Dr. Lindsey Votaw, Pharm.D., CGP, BCPS

WORKSHOP 6 Towards European consensus indications for major antibiotic classes: an exercise with the macrolides. Objectives

Introduction to Chemotherapeutic Agents. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The university of Jordan November 2018

Cipro for klebsiella uti

JAC Bactericidal index: a new way to assess quinolone bactericidal activity in vitro

Principles of Antimicrobial therapy

Choosing the Ideal Antibiotic Therapy and the Role of the Newer Fluoroquinolones in Respiratory Tract Infections

Pinni Meedha Mojutho Ammanu Dengina Koduku Part 1 Kama Kathalu

SUMMARY OF PRODUCT CHARACTERISTICS

Principles of Infectious Disease. Dr. Ezra Levy CSUHS PA Program

The β- Lactam Antibiotics. Munir Gharaibeh MD, PhD, MHPE School of Medicine, The University of Jordan November 2018

SUMMARY OF PRODUCT CHARACTERISTICS. Enrotron 50 mg/ml Solution for injection for cattle, pigs, dogs and cats

UTI Dr S Mathijs Department of Pharmacology

Pharmaceutical Form Ciprofloxacin 2 mg/ml Solution for infusion. Applicant Name Strength. Ciprofloxacin Nycomed. Ciprofloxacin Nycomed

Approach to pediatric Antibiotics

Burton's Microbiology for the Health Sciences. Chapter 9. Controlling Microbial Growth in Vivo Using Antimicrobial Agents

Other ingredients are sodium chloride and purified water.

03/09/2014. Infection Prevention and Control A Foundation Course. Talk outline

Introduction to Antimicrobial Therapy

DOSAGE FORMS AND STRENGTHS Otic Suspension: Each OTIPRIO vial contains 1 ml of 6% (60 mg/ml) ciprofloxacin otic suspension. (3)

Chapter 46. Sulfonamides, Trimethoprim, & Quinolones

Summary of Product Characteristics

The Rise of Antibiotic Resistance: Is It Too Late?

Reduce the risk of recurrence Clear bacterial infections fast and thoroughly

Comparative In Vitro Activity of Prulifloxacin against Bacteria Isolated from Hospitalized Patients at Siriraj Hospital

Principles of Antimicrobial Therapy

OBSTETRICS & GYNAECOLOGY. Penicillin G 5 million units IV ; followed by 2.5 million units 4hourly upto delivery

Principles of Anti-Microbial Therapy Assistant Professor Naza M. Ali. Lec 1

Chapter 51. Clinical Use of Antimicrobial Agents

12 TIPS HOW TO TREAT BACTERIAL INFECTION WITHOUT ANTIBIOTICS

Fluoroquinolines: Past, Present and Future of a Novel Group of Antibacterial Agents

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Recommended for Implementation at Step 7 of the VICH Process on 15 December 2004 by the VICH Steering Committee

Pharm 262: Antibiotics. 1 Pharmaceutical Microbiology II DR. C. AGYARE

SUMMARY OF PRODUCT CHARACTERISTICS

Summary of Product Characteristics 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Enrotab 50 mg tablets for dogs

4.5. Special precautions for use Special precautions to be taken by person administering the veterinary medicinal product to animals

CHAPTER:1 THE RATIONAL USE OF ANTIBIOTICS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Pharmacology Week 6 ANTIMICROBIAL AGENTS

IV Antibiotics for Lyme Disease (Ceftriaxone, Cefotaxime sodium, Doxycycline, Penicillin G potassium)

GENERAL NOTES: 2016 site of infection type of organism location of the patient

Antibiotics in the future tense: The Application of Antibiotic Stewardship in Veterinary Medicine. Mike Apley Kansas State University

Discover the. Discover the. innovative science. Veraflox (pradofloxacin) Veraflox. Efficacy. Safety. Ease-of-use.

Give the Right Antibiotics in Trauma Mitchell J Daley, PharmD, BCPS

SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE VETERINARY MEDICINAL PRODUCT. Marbotab P 20 mg tablets for dogs and cats

Safe Patient Care Keeping our Residents Safe Use Standard Precautions for ALL Residents at ALL times

Unique, fast-acting, and long-lasting injectables for livestock health & nutrition

Antibiotics in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Comparative studies on pulse and continuous oral norfloxacin treatment in broilers and turkeys. Géza Sárközy

Prophylactic antibiotic timing and dosage. Dr. Sanjeev Singh AIMS, Kochi

MARBOCYL 10% SUMMARY OF PRODUCT CHARACTERISTICS

number Done by Corrected by Doctor

Pharmacokinetics. Absorption of doxycycline is not significantly affected by milk or food, but coadministration of antacids or mineral supplements

Initial Management of Infections in the Era of Enhanced Antimicrobial Resistance

ANTIMICROBIAL DOSING GUIDE 2013

Update on Fluoroquinolones. Charles Krasner, M.D. June 16, 2016 Antibiotic Stewardship Program -ECHO

INFECTIONS IN CHILDREN-ANTIMICROBIAL MANAGEMENT

Similar to Penicillins: -Chemically. -Mechanism of action. -Toxicity.

number Done by Corrected by Doctor

Overview of Infection Control and Prevention

11/10/2016. Skin and Soft Tissue Infections. Disclosures. Educational Need/Practice Gap. Objectives. Case #1

Protein Synthesis Inhibitors

Advanced Practice Education Associates. Antibiotics

SUMMARY OF PRODUCT CHARACTERISTICS. 1. NAME OF THE VETERINARY MEDICINAL PRODUCT Vetrisulf powder for oral solution for chickens, turkeys and geese

4 th and 5 th generation cephalosporins. Naderi HR Associate professor of Infectious Diseases

In Vitro Antimicrobial Activity of CP-99,219, a Novel Azabicyclo-Naphthyridone

ANTIBIOTICS: TECHNOLOGIES AND GLOBAL MARKETS

Einheit für pädiatrische Infektiologie Antibiotics - what, why, when and how?

Development of Resistant Bacteria Isolated from Dogs with Otitis Externa or Urinary Tract Infections after Exposure to Enrofloxacin In Vitro

SUMMARY OF PRODUCT CHARACTERISTICS

DNA Gyrase Inhibitors, Sulfa drugs and VRE

PDF hosted at the Radboud Repository of the Radboud University Nijmegen

AZITHROMYCIN, DOXYCYCLINE, AND FLUOROQUINOLONES

What bugs are keeping YOU up at night?

Approved by the Food Safety Commission on September 30, 2004

Antimicrobial Stewardship Strategy: Antibiograms

Fluoroquinolone. CIPRO and AVELOX. Briefing Book. For the FDA Advisory Committee Meeting. 5 November 2015

مادة االدوية المرحلة الثالثة م. غدير حاتم محمد

Antibiotics (2): - Before you start: this lecture has a lot of names and things get entangled together, but I

Practical part: Evaluation of microbial cell morphology under the light microscope and practice of Gram staining technique.

1/30/ Division of Disease Control and Health Protection. Division of Disease Control and Health Protection

Microbiology ( Bacteriology) sheet # 7

Copy in the header and footer will not appear on the final printed label LAB0042 Prepared: 28/02/01 SYRINGE LABEL

Cleaning and Disinfection Protocol Vegetative Bacteria

Antibiotic. Antibiotic Classes, Spectrum of Activity & Antibiotic Reporting

folate-derived cofactors purines pyrimidines Sulfonamides sulfa drugs Trimethoprim infecting bacterium to perform DNA synthesis cotrimoxazole

Cephalosporins, Quinolones and Co-amoxiclav Prescribing Audit

For the use only of Registered Medical Practitioners or a Hospital or a Laboratory NEOSPORIN SKIN / ANTIBIOTIC OINTMENT

Transcription:

THE QUINOLONES Third Edition Edited by VINCENT T. ANDRIOLE Yale University School of Medicine ACADEMIC PRESS San Diego London Boston New York Sydney Tokyo Toronto

CONTENTS Contrihuttirs Prc face xv xix 1 The Quinolone.s: History and Overview I'iki Hull Introduction Structure-Activitv Relationships (SARs) Antibacterial Activity Mode of Action Spectrum of Activity Bacterial Resistance to Fluoroquinolones Clinical Pharmacology Penetration into Respiratory Tissues Elimination Pathways Pharmacodynamics of Quinolones Clinical Uses Urinary Tract Infections Sexually Transmitted Diseases Respiratory Infections Gastrointestinal Infections Skin and Soft Tissue Infections Bone Infections Neutropenic Cancer Patients Prophylaxis Pharmacoeconomic Aspects of Fluoroquinolone Usage Use of Fluoroquinolones in Pediatrics Adverse Drug Reactions 2 3 6 6 6 8 9 10 11 12 12 12 13 13 14 15 15 16 16 16 17 19

VI Contents Interactions with Other Drugs 22 Interactions Reducing Absorption 22 Metabolic and Inhibitory Interactions 23 Conclusion 23 References 24 2 Chemistry and Mechanism of Action of the Quinolone Antibacterials Katherine E. Brighty and Thomas D. Gootz Introduction Structural and Historical Background General Structural Features of the Quinolones First-Generation Quinolones Second-Generation Quinolones Third- and Fourth-Generation Quinolones In Vitro Potency In Vivo Activity Selectivity: Activity against Mammalian Topoisomerase II and Genetic Toxicity Chemical Properties Future Directions Compounds Lacking the C-6 Fluorine 2-Pyridones Alteration of Primary Enzymatic Target Mechanism of Action Replication of DNA Bacterial Topoisomerases Topoisomerase Sensitivity to Fluoroquinolones Killing of Bacterial Cells by Fluoroquinolones Conclusion References 34 34 35 36 38 42 43 51 53 55 57 57 59 60 61 61 63 71 75 81 82 3 Comparative In-Vitro Properties of the Quinolones Ian Phillips, Anna King, and Kevin Shannon Introduction 99 Gram-Negative Aerobes 102 Enterobacteriaceae 102 Other Gram-Negative Aerobes 107 Gram-Positive Aerobes 117 Anaerobes 125 Miscellaneous Organisms 130

Contents Vll Conclusion 132 References 132 Bacterial Resistance to Quinolones: Mechanisms and Clinical Implications Thilo Kohler and Jean-Claude Pechere Introduction 140 Mechanisms of Quinolone Resistance 140 Gram-Negative Bacteria 140 Escherichia coli 140 Salmonella spp. 142 Klebsiella spp. 143 Pseudomonas aeruginosa 143 Neisseria gonorrhoeae 145 Campylobacter spp. 145 Helicobacter pylori 145 Miscellaneous '46 Gram-Positive Bacteria '46 Staphylococcus aureus '46 Streptococcus pneumoniae '47 Enterococcus faecalis 14 Mycobacteria '4s Clinical Impact of Bacterial Resistance to Quinolones 149 Prevalence of Quinolone Resistance 149 Fluoroquinolone Resistance in Hospital Practice 149 Fluoroquinolone Resistance in Community-Acquired Infections 151 Quinolone Use and Emergence of Resistance 155 References '^ Pharmacokinetics and Pharmacodynamics of the Fluoroquinolones Myo-Kyoung Kim and Charles H. Nightingale Introduction Basic Concepts of Pharmacokinetics and Pharmacodynamics 170 Pharmacokinetics Absorption 17"* 174 Distribution Elimination 179 1 X1 Special Population Drug Interactions l7

Contents Pharmacodynamics 185 Bactericidal Activity: Time-Kill Curves 185 Pharmacodynamic Surrogate Markers and Clinical Outcome 186 Post-Antibiotic Effects 188 Conclusion 191 References 191 6 Use of Quinolones in Urinary Tract Infection and Prostatitis Lindsay E. Nicolle Introduction 203 Urinary Tract Infection 204 Pharmacology 207 Microbiology 207 Clinical Studies 209 Limitations of Available Studies 209 Acute Uncomplicated Urinary Infection 209 Acute Nonobstructive Pyelonephritis 213 Complicated Urinary Infection 214 Bacterial Prostatitis 215 Conclusion 218 References 218 7 Use of the Quinolones in Sexually Transmitted Diseases Richard P. DiCarlo and David H. Martin Introduction 228 Gonococcal Infections 229 Background 229 In-Vitro Activity of Quinolones against Neisseria gonorrhoeae 230 Clinical Studies 230 Resistance of N. gonorrhoeae to the Quinolones 233 Chlamydia trachomatis 235 Background 235 In-Vitro Activity of Quinolones against C. trachomatis 235 Clinical Studies 235 Pelvic Inflammatory Disease 238 Chancroid 239 Background 239 In-Vitro Activity of Quinolones against Haemophilus ducreyi 239 Clinical Studies 240 Donovanosis 241 Bacterial Vaginosis 241

Contents IX Special Toxicity Considerations When Quinolones Are Used for Treating Sexually Transmitted Diseases 242 Conclusion 243 References 243 8 Treatment of Respiratory Infections with Quinolones Paul B. Iannini, Michael S. Niederman, and Vincent T. Andriole Introduction 255 Clinical Issues in the Therapy of Respiratory Infection 257 Community-Acquired Pneumonia 257 Hospital-Acquired Pneumonia 260 Acute Exacerbations of Chronic Bronchitis 261 Pharmacological Advantages for the Use of Quinolones in Respiratory Infection 262 Penetration into Lung Tissue 262 Mechanism of Killing 265 Microbiologic Advantages of Quinolones for Respiratory Infection 267 Activity against Common Respiratory Pathogens 268 Clinical Efficacy of Quinolones for the Therapy of Respiratory Tract Infections 271 Community-Acquired Pneumonia 271 Hospital-Acquired Pneumonia 274 Acute Exacerbations of Chronic Bronchitis 275 Conclusion 276 References 277 9 Use of Quinolones in Surgery and Obstetrics and Gynecology John Weigelt, Karen Brasel, and Sebastian Faro Introduction 285 Surgical Wound Prophylaxis 286 Soft Tissue Infection 288 Intraabdominal Infection 289 Gynecologic Infections 291 Postoperative Pelvic Infections 293 Pelvic Inflammatory Disease 294 Upper Genital Tract Infection 295 Pregnancy 296 Conclusion 297 References 297

X Contents 10 Use of the Quinolones for Treatment and Prophylaxis of Bacterial Gastrointestinal Infections Davidson H. Hamer and Sherwood L. Gorbach Introduction 304 Pharmacology 304 Microbiology 304 Effects on Human Intestinal Microflora 305 Clinical Studies 305 Empirical Therapy of Acute Diarrhea 305 Traveler's Diarrhea 308 Nontyphoidal Salmonellosis 309 Typhoid Fever 310 Shigellosis 312 Cholera and Other Vibrios 314 Campylobacter 315 Antimicrobial Resistance to Quinolones 316 Conclusion 317 References 318 11 Use of the Quinolones in Treatment of Bacterial Meningitis Rodrigo Hasbun and Vincent J. Quagliarello Introduction 325 Pharmacology 326 In-Vitro Activity of Quinolones against Meningeal Pathogens 326 CSF Penetration of the Quinolones in Vivo 328 Microbiology 335 Studies of Clinical Efficacy 336 Case Reports 336 Chemoprophylaxis of Meningococcal Meningitis 336 Clinical Trial of Trovafloxacin 338 Conclusion 339 References 339 12 Use of the Quinolones in Immunocompromised Patients Kenneth V. I. Rolston Introduction 343 Risk Factors and Associated Infections 344

Contents XI Rationale for Fluoroquinolone Use 346 Effect of Fluoroquinolones on Endogenous Microflora 347 Infection Prevention in Afebrile Neutropenic Patients 348 Empiric Therapy in Febrile Neutropenic Patients 350 Risk-Based Therapy for Febrile Neutropenia 352 Treatment of Specific Infections 354 Legionellosis 354 Mycobacterial Infections 356 Miscellaneous Infections 358 Conclusion 359 References 360 13 Use of the Quinolones in Skin and Skin Structure (Osteomyelitis) and Other Infections Adolf W. Karchmer Introduction 371 Skin and Soft Tissue Infection 372 Pharmacology 373 Microbiology 373 Clinical Studies 374 Bone and Joint Infection 378 Osteomyelitis 378 Pharmacology 379 Microbiology 380 Clinical Studies 382 Septic Arthritis 388 Conclusion 389 References 390 14 Safety Overview: Toxicity, Adverse Effects, and Drug Interactions Ralf Stahlmann and Hartmut Lode Introduction 398 Toxicity of Quinolones (Studies in Animals) 399 General Remarks 399 Effects on Connective Tissue Structures (Cartilage, Tendon) 400 Neurotoxicity 404 Phototoxicity, Photomutagenicity, and Photocarcinogenicity 405

Xll Contents Nephrotoxicity 406 Ocular Toxicity 407 Cardiotoxicity 408 Reproductive and Developmental Toxicity 408 Mutagenicity and Carcinogenicity 411 Adverse Effects of Fluoroquinolones in Clinical Studies 413 Adverse Effects of Fluoroquinolones 413 Adverse Effects Observed in Preregistration Clinical Trials 420 Adverse Effects Observed in Comparative Double-Blind Studies 429 Drug Interactions 433 Influence of ph and Magnesium on Antibacterial Activity of Quinolones in Vitro 434 Interactions between Quinolones and Antacids 434 Influence of Breakfast or Dairy Products on the Bioavailability of Quinolones 436 Interactions in Renal Elimination 438 Interactions between Quinolones and Theophylline 438 Interactions between Quinolones and Caffeine 440 Interactions with Digoxin 440 Interactions between Quinolones and Other Drugs 441 References 442 15 Use of the Quinolones in Pediatrics Urs B. Schaad Introduction 455 Animal Data 456 Quinolone Arthropathy 456 Histopathology 457 Possible Mechanisms 458 Tendopathy 458 Pharmacokinetics 460 Clinical Experiences 460 Tolerability 460 Development of Resistance 461 Quinolone-Associated Arthralgia 462 Studied Indications 463 Newest Compounds 467 Recommendations 468 Conclusion 468 References 469

Contents Xlll 16 The Quinolones: Prospects Vincent T. Andriole Introduction 477 Molecular Mechanisms of the Quinolones: Key Discoveries 478 Microbiology 480 Pharmacokinetics 481 Clinical Uses 482 Adverse Events 483 Quinolones: Future Developments 486 Current Quinolone Status and Classification 487 Conclusion 490 References 491 Index 497